JAK inhibitorFDA-approvedFirst-line
Ruxolitinib
How it works
Blocks the JAK1 and JAK2 enzymes, which are overactive in myeloproliferative neoplasms, reducing inflammation and promoting apoptosis.
Cancer types
Leukemia— ALL
Efficacy
In clinical trials, around 50% of patients achieved a hematologic response, with a median time to first hematologic response of approximately 2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a Combination of Medications for Relapsed/Refractory T-cell Prolymphocytic Leukemia | Leukemia | phase-1 | — | Source → |
| Rare lung condition linked to medication | Leukemia | observational | — | Source → |
| Testing CART123 Cells with or without Ruxolitinib in Relapsed/Refractory AML | Leukemia | phase-1 | — | Source → |
| Ruxolitinib for Stage IV Non-Small Cell Lung Cancer Cachexia | Lung Cancer | phase-1 | — | Source → |
| Evaluating ruxolitinib and panobinostat in blood disorders | Leukemia | preclinical | — | Source → |
| Combining Ruxolitinib with Chemotherapy for Relapsed Leukemia | Leukemia | phase-1/2 | Only 1 out of 10 patients receiving ruxolitinib achieved complete remission with incomplete platelet count recovery. | Source → |
| New Treatment Option for Rare Blood Disorder | Leukemia | phase-2 | Ruxolitinib yielded an overall response rate of 86%. | Source → |
| New Options for Polycythemia Vera Treatment | Leukemia | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.